Dendrite (NASDAQ:DRTE)
Historical Stock Chart
From Jun 2019 to Jun 2024
Dendrite International, Inc. (NASDAQ: DRTE) today announced that its
proposed acquisition by French company, Cegedim SA (“Cegedim”),
has cleared U.S. antitrust review, but remains subject to satisfaction
of several other conditions, including the transaction’s
approval by Dendrite’s shareholders.
On March 2, 2007, Dendrite announced that it had entered into an
agreement to be acquired by Cegedim in a merger transaction. Cegedim has
agreed to pay $16.00 per common share of Dendrite upon the closing of
the merger. On March 19, 2007, Dendrite and Cegedim submitted pre-merger
notification and report forms with the U.S. Federal Trade Commission and
the U.S. Department of Justice, Antitrust Division. The granting of
early termination of the waiting period under the Hart-Scott-Rodino
Antitrust Improvements Act of 1976, as amended, means the proposed
acquisition has cleared U.S. antitrust review.
About Dendrite
Founded in 1986, Dendrite International (NASDAQ: DRTE) enables sales,
marketing, clinical and compliance solutions for the global
pharmaceutical industry. The Company’s clients
are located in more than 50 countries and include the world’s
top 20 pharmaceutical companies. For more information, please visit http://www.dendrite.com.
Note: Dendrite is a registered trademark of Dendrite International, Inc.
Forward Looking Statements
This press release contains certain statements that are “forward-looking
statements” within the meaning of Section 27A
of the Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934, as amended. Such statements are qualified by the inherent
risks and uncertainties surrounding future expectations generally, and
also may materially differ from actual future experience involving any
one or more of such statements. Such risks and uncertainties include:
Dendrite’s inability to satisfy the conditions
to closing the merger (including shareholder approval) and other risk
factors as set forth from time to time in Dendrite’s
filings with the SEC. The inclusion of a forward-looking statement
herein should not be regarded as a representation by Dendrite that
Dendrite’s objectives will be achieved.
Dendrite undertakes no obligation to publicly update forward-looking
statements, whether as a result of new information, future events or
otherwise.
Additional Information and Where to Find It
In connection with the proposed merger and required shareholder
approval, Dendrite filed with the SEC a definitive proxy statement. The
definitive proxy statement has been mailed to the shareholders of
Dendrite. Dendrite’s shareholders are urged
to read the definitive proxy statement because the definitive proxy
statement contains important information about the acquisition and
Dendrite. Investors and security holders may obtain free copies of these
documents and other documents filed with the SEC at the SEC’s
web site at www.sec.gov. In addition,
investors and security holders may obtain a free copy of the proxy
statement and other documents filed by Dendrite with the SEC at the SEC’s
web site at www.sec.gov. These
documents may be accessed and downloaded for free at Dendrite’s
web site at www.dendrite.com or by
directing a request to investorrelations@dendrite.com.
Dendrite and its officers and directors may be deemed to be participants
in the solicitation of proxies from Dendrite shareholders in respect of
the proposed merger. Information regarding the officers and directors of
Dendrite and their ownership of Dendrite stock is set forth in the
definitive proxy statement, which was filed with the SEC on April 9,
2007. Investors and security holders may obtain more detailed
information regarding the direct and indirect interests of Dendrite and
its respective executive officers and directors in the merger by reading
the definitive proxy statement which is available free at the SEC's
website, http://www.sec.gov, and at
Dendrite's website, http://www.dendrite.com.